Xilio Therapeutics Inc. (XLO)
1.08
-0.02 (-1.82%)
At close: Jan 14, 2025, 3:59 PM
1.10
1.85%
After-hours Jan 14, 2025, 04:21 PM EST
undefined% (undefined)
| Bid | 1 |
| Market Cap | 47.47M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.55 |
| PE Ratio (ttm) | -0.7 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.08 |
| Volume | 80,854 |
| Avg. Volume (20D) | 522,954 |
| Open | 1.11 |
| Previous Close | 1.10 |
| Day's Range | 1.05 - 1.11 |
| 52-Week Range | 0.50 - 1.93 |
| Beta | undefined |
About XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2021
Employees 73
Stock Exchange NASDAQ
Ticker Symbol XLO
Website https://www.xiliotx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for XLO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 270.37% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Xilio Therapeutics Inc. is scheduled to release its earnings on Mar 31, 2025,
during market hours.
Analysts project revenue of $3.30M, reflecting a n/a YoY growth and earnings per share of -0.26, making a -59.38% decrease YoY.
Analysts project revenue of $3.30M, reflecting a n/a YoY growth and earnings per share of -0.26, making a -59.38% decrease YoY.
3 weeks ago ·
Source
+8.25%
Xilio Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
2 months ago ·
Source
-19.38%
Xilio Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results.
